Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Novak

Showing results (731-740 of 826) with videos related to

Pageof 83
Sort By:
Medrxiv : the Preprint Server for Health Sciences|June 19, 2023
Multiomic Analysis Identifies a High-Risk Metabolic and TME Depleted Signature that Predicts Early Clinical Failure in DLBCLKerstin Wenzl, Matt Stokes, Joseph P Novak, et al.
Blood Cancer Journal|June 20, 2024
Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCLKerstin Wenzl, Matthew E Stokes, Joseph P Novak, et al.
American Journal of Hematology|October 29, 2017
MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemiaJithma P Abeykoon, Jonas Paludo, Rebecca L King, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 21, 2012
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencingJens G Lohr, Petar Stojanov, Michael S Lawrence, et al.
American Journal of Hematology|December 10, 2019
Impact of MYD88<sup>L265P</sup> mutation status on histological transformation of Waldenström MacroglobulinemiaSaurabh Zanwar, Jithma P Abeykoon, Eric Durot, et al.
American Journal of Epidemiology|January 6, 2010
Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph ConsortiumChristine F Skibola, Paige M Bracci, Alexandra Nieters, et al.
Blood|October 11, 2012
PRRC2A and BCL2L11 gene variants influence risk of non-Hodgkin lymphoma: results from the InterLymph consortiumAlexandra Nieters, Lucia Conde, Susan L Slager, et al.
Science (New York, N.Y.)|November 2, 2021
An oral SARS-CoV-2 M<sup>pro</sup> inhibitor clinical candidate for the treatment of COVID-19Dafydd R Owen, Charlotte M N Allerton, Annaliesa S Anderson, et al.
Nature Medicine|June 30, 2018
Publisher Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomesBjoern Chapuy, Chip Stewart, Andrew J Dunford, et al.
Nature Medicine|May 2, 2018
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomesBjoern Chapuy, Chip Stewart, Andrew J Dunford, et al.
Pageof 83

Showing results (731-740 of 826) with videos related to

Sort By:
Pageof 83
Medrxiv : the Preprint Server for Health Sciences|June 19, 2023
Multiomic Analysis Identifies a High-Risk Metabolic and TME Depleted Signature that Predicts Early Clinical Failure in DLBCLKerstin Wenzl, Matt Stokes, Joseph P Novak, et al.
Blood Cancer Journal|June 20, 2024
Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCLKerstin Wenzl, Matthew E Stokes, Joseph P Novak, et al.
American Journal of Hematology|October 29, 2017
MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemiaJithma P Abeykoon, Jonas Paludo, Rebecca L King, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 21, 2012
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencingJens G Lohr, Petar Stojanov, Michael S Lawrence, et al.
American Journal of Hematology|December 10, 2019
Impact of MYD88<sup>L265P</sup> mutation status on histological transformation of Waldenström MacroglobulinemiaSaurabh Zanwar, Jithma P Abeykoon, Eric Durot, et al.
American Journal of Epidemiology|January 6, 2010
Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph ConsortiumChristine F Skibola, Paige M Bracci, Alexandra Nieters, et al.
Blood|October 11, 2012
PRRC2A and BCL2L11 gene variants influence risk of non-Hodgkin lymphoma: results from the InterLymph consortiumAlexandra Nieters, Lucia Conde, Susan L Slager, et al.
Science (New York, N.Y.)|November 2, 2021
An oral SARS-CoV-2 M<sup>pro</sup> inhibitor clinical candidate for the treatment of COVID-19Dafydd R Owen, Charlotte M N Allerton, Annaliesa S Anderson, et al.
Nature Medicine|June 30, 2018
Publisher Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomesBjoern Chapuy, Chip Stewart, Andrew J Dunford, et al.
Nature Medicine|May 2, 2018
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomesBjoern Chapuy, Chip Stewart, Andrew J Dunford, et al.
Pageof 83